Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes

Completed · Phase 3

Conditions studied: Type 2 Diabetes

In brief

This extension study is designed to evaluate the long-term safety and tolerability of colesevelam hydrochloride (WelChol®) in patients with type 2 diabetes.

Key facts

Study ID

NCT00151762

Run by

Daiichi Sankyo

People needed

780

Starts

2004-12-01

Expected to finish

2007-07-01

Last updated by the study team

2008-01-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Tuscumbia, Alabama, United States
• Study site — Jonesboro, Arkansas, United States
• Study site — Little Rock, Arkansas, United States
• Study site — Searcy, Arkansas, United States
• Study site — Carmichael, California, United States
• Study site — Concord, California, United States
• Study site — Irvine, California, United States
• Study site — La Jolla, California, United States
• Study site — Los Angeles, California, United States
• Study site — Los Gatos, California, United States
• Study site — San Diego, California, United States
• Study site — Spring Valley, California, United States
• Study site — West Hills, California, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Cocoa Beach, Florida, United States
• Study site — Coral Gables, Florida, United States
• Study site — Largo, Florida, United States
• Study site — Miami, Florida, United States
• Study site — New Port Richey, Florida, United States
• Study site — Pembroke Pines, Florida, United States
• Study site — West Palm Beach, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Evansville, Indiana, United States
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.